Latent Tuberculosis Detection Market 2035: Innovation in Diagnostic Testing

Introduction:

The Global Latent Tuberculosis Infection Detection Market is witnessing steady growth, driven by increasing awareness of tuberculosis prevention, rising demand for early diagnosis, and expanding government initiatives to control TB transmission. Latent tuberculosis infection (LTBI) detection helps identify individuals infected with Mycobacterium tuberculosis who do not exhibit symptoms of active tuberculosis but may develop the disease in the future. Advancements in diagnostic technologies, including interferon-gamma release assays (IGRAs), improved tuberculin skin tests, and automated laboratory testing, are supporting more effective screening strategies. Growing public health investments, increased screening of high-risk populations, and expanding access to diagnostic services are expected to support long-term market growth globally.

Get Free Sample Of This Premium Report:

https://www.decisionsadvisors.com/request-sample/DAR4394

Latent Tuberculosis Infection Detection Market Insights

According to Decisions Advisors, the Global Latent Tuberculosis Infection Detection Market was valued at USD 1.84 Billion in 2024 and is projected to reach USD 3.38 Billion by 2035.

From 2025 to 2035, the market is expected to grow at a CAGR of 5.68%. Within the Test Type category, Tuberculin Skin Tests (TST) held the largest market share in 2024, supported by their widespread availability and established use in tuberculosis screening programs.

Within the Brand category, QFT-Plus (QuantiFERON-TB Gold Plus) accounted for the largest market share in 2024, supported by its established role in interferon-gamma release assay testing.

Within the Application category, People Living with HIV (PLHIV) represented the largest market segment in 2024, reflecting the importance of TB screening among populations at increased risk of developing active tuberculosis

Other Key Findings

• Asia-Pacific accounted for the largest share of the global Latent Tuberculosis Infection Detection Market, supported by a high TB burden and expanding screening initiatives.
• Europe is expected to be the fastest-growing regional market during the forecast period, driven by public health screening programs and increasing adoption of advanced diagnostic technologies.
• Growing government investment in TB prevention, early detection, and preventive treatment is creating opportunities for diagnostic manufacturers.
• Advancements in IGRA technologies, laboratory automation, and cost-effective skin tests are helping improve screening accessibility and efficiency.
• Screening of household contacts, healthcare workers, migrants, and other high-risk populations continues to support demand for latent TB testing.
• Limited access to advanced diagnostic facilities, test-result variability, and the cost of specialized testing remain important challenges in some regions.

Report Summary

Segmentation Covered

Report Coverage

Revenue Forecast, Competitive Landscape, Growth Drivers, Industry Trends, Diagnostic Technology Advancements, TB Screening Programs, Public Health Initiatives, Regulatory Landscape, Market Opportunities, and Regional Analysis.

Companies

Abbott Laboratories, Aid Autoimmun Diagnostika GmbH, ARKRAY, Inc., Beijing Wantai Biopharmaceutical Co., Ltd., bioMérieux, Boditech Med Inc., Lionex GmbH, Oxford Immunotec (Revvity), QIAGEN, Sanofi, SD Biosensor, Inc., Serum Institute of India Pvt. Ltd., and Others.

Want detailed insights, forecasts, and competitive analysis?

Check out the full report now:

https://www.decisionsadvisors.com/reports/latent-tuberculosis-infection-detection-market